Fagron Sa · EURONEXT:FAGR
Fagron Sa — 9M 2024 Earnings Presentation
10 slides from Fagron Sa's earnings presentation, Oct 10, 2024
Slide 1: 9M 2024 Trading Update
9M 2024 Trading Update Rafael Padilla CEO | Karin de Jong CFO 10 October 2024
Slide 2: Disclaimer
Disclaimer The contents of this document, including all statements made therein, are based on estimates, assumptions and other information currently available to the management of Fagron. Certain statements in this presentation may be deemed to be forward-looking. Such forward-looking statements are
Slide 3: Continued momentum with outstanding Q3 performance
Continued momentum with outstanding Q3 performance Revenue growth of 12.1% driven by organic growth in Q3 2024 9M 2024 all regions and acquisitions Total revenue €214.5m €643.8m Organic growth at CER supported by strong performances at FSS and B&E in North America, Brands in Latin America and EMEA C
Slide 4: Revenue growth underpinned by all regions and acquisitions
Revenue growth underpinned by all regions and acquisitions Revenue bridge (€ m) 700.0 16.3 650.0 53.8 -6.2 600.0 9.4 7.5 550.0 643.8 500.0 563.0 450.0 9M 2023 EMEA Latin America North America Acquisitions FX 9M 2024 EMEA Latin America North America +10.2% +3.4% +24.4% 300.0 200.0 180.0 300.0 279.9 2
Slide 5: Leveraging operational efficiencies and market positioning
Leveraging operational efficiencies and market positioning EMEA Latin America North America +11.2% -2.6% +21.1% 100.0 80.0 120.0 90.0 70.0 96.9 80.0 73.6 100.0 70.0 66.2 60.0 45.2 44.1 80.0 80.0 50.0 60.0 27.8 1.0 50.0 23.3 40.0 1.1 60.0 72.2 14.6 16.0 58.2 40.0 11.0 11.1 30.0 40.0 30.0 20.0 20.0 31
Slide 6: Consolidation and efficiencies through disciplined M&A approach
Consolidation and efficiencies through disciplined M&A approach Acquired raw material part of Acquired book of business, including: business - Customer base Rationale: - Inventory EuroOTC - Increase footprint in Germany - Sales force EMEA - Scale and sourcing benefits Rationale: through integration
Slide 7: Quality focus remains a key strategic priority
Quality focus remains a key strategic priority 9M 2024 Global quality KPIs Latest audits – North America Number of facilities to audit globally Audits globally 1 Anazao, Las Vegas 35 17 Number of inspectional observations: 3 Observations have been addressed 2 FSS, Wichita Regulatory bodies Warning l
Slide 8: FY 2024 outlook
FY 2024 outlook FY 2024 FY 2024 Capex Revenue REBITDA margin €850 – €870m Increase in 3.0 – 3.5% profitability y-o-y of revenue* Guidance assumes no significant changes in current market conditions *Excludes one-off capex projects. 8
Slide 9: Together
Global leader in niche pharmaceutical compounding market Strong Cash Operational Sustainability Disciplined Generation Excellence Focus M&A Defensive Unique Market Business Model Positioning Together we create the future of personalized medicine 9
Slide 10: Questions
• Key Highlights Questions